Impact of Homeopathy for Persistent Insomnia in Patients With Cancer

Randomized Controlled Trial of Homeopathy Compared With Treatment As Usual for Persistent Insomnia in Patients With Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02515006

Enrollment

160

Registered

2015-08-04

Start date

2014-09-30

Completion date

2015-06-30

Last updated

2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Chronic Insomnia

Brief summary

Persistent insomnia is highly prevalent complaint in cancer survivors, but is seldom satisfactorily addressed. The adaptation to cancer care of a validated, cost-effective intervention may offer a practicable solution. The aim of this study was to investigate the clinical effectiveness of homeopathy for insomnia.

Interventions

OTHERHomeopathy Medicine

Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* scheduled to begin chemotherapy or radiotherapy * chemotherapy or radiotherapy * meet diagnostic criteria for chronic insomnia (i.e., lasting for at least one month) * Chronic insomnia has been defined in previous research:as the presence of (1) three or more episodes of insomnia (i.e., ≥ 30minuteSOL, ≥ 60minute wake after sleep onset (WASO), or ≤ 6.5 hour total sleep time (TST) per night) of per week and (2) daytime effects of insomnia, such as irritability, difficulty concentrating, or fatigue for at least one month. * have the permission of their oncologists to participate.

Exclusion criteria

* untreated alcohol or substance abuse or dependence, * bipolar, or psychotic disordermedical conditions such as seizure disorder, restless leg disorder, or Parkinson's disease * untreated sleep disorders such as sleep apnea * Taking other alternative medicines

Design outcomes

Primary

Measure	Time frame
Changes in sleep efficiency on the Insomnia Severity Index	From baseline to 6 Months

Secondary

Measure	Time frame
Change in Anxiety and Depression on Hospital Anxiety Depression Scale	From Baseline to 6 Months
Change in Quality of Life on Short Form-36 Scale	From Baseline to 6 Months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026